Literature DB >> 20601655

Interleukin-18 is a key mediator in dermatomyositis: potential contribution to development of interstitial lung disease.

Takahisa Gono1, Yasushi Kawaguchi, Tomoko Sugiura, Hisae Ichida, Kae Takagi, Yasuhiro Katsumata, Masanori Hanaoka, Yuko Okamoto, Yuko Ota, Hisashi Yamanaka.   

Abstract

OBJECTIVE: To determine whether IL-18 is involved in the inflammation of DM and PM.
METHODS: Thirty-three patients with DM were enrolled in this study, including 25 with interstitial lung disease (ILD). In addition, 16 patients with PM were enrolled, including 6 with ILD. All patients were admitted to our hospital as a result of their condition requiring treatment, and clinical laboratory data including serum IL-18 were recorded on admission.
RESULTS: Serum IL-18 was significantly (P < 0.0001) higher in both DM and PM patients than in healthy controls (n = 30). Serum ferritin and IL-18 were significantly (P = 0.003 and 0.0044, respectively) higher in DM than in PM patients. Additionally, ferritin and IL-18 were significantly (P = 0.023 and 0.034, respectively) higher in DM patients with ILD than in DM patients without ILD. Significant positive correlations were found between creatine kinase (CK) and ferritin (r(s) = 0.39, P = 0.024); CK and IL-18 (r(s) = 0.48, P = 0.005); and IL-18 and ferritin (r(s) = 0.54, P = 0.0012) in the DM group as a whole. These findings were different for the DM plus ILD subgroup: significant positive correlations were found between CK and ferritin (r(s) = 0.40, P = 0.047); CK and IL-18 (r(s) = 0.63, P = 0.0008); and IL-18 and ferritin (r(s) = 0.41, P = 0.042).
CONCLUSION: Serum IL-18 was strikingly elevated in patients with DM and was associated particularly with disease activity and ILD complication in DM.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20601655     DOI: 10.1093/rheumatology/keq196

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  23 in total

Review 1.  Interstitial lung disease in myositis: clinical subsets, biomarkers, and treatment.

Authors:  Tsuneyo Mimori; Ran Nakashima; Yuji Hosono
Journal:  Curr Rheumatol Rep       Date:  2012-06       Impact factor: 4.592

Review 2.  Pathogenesis of dermatomyositis: role of cytokines and interferon.

Authors:  Lily Kao; Lorinda Chung; David F Fiorentino
Journal:  Curr Rheumatol Rep       Date:  2011-06       Impact factor: 4.592

Review 3.  Causes and consequences of endoplasmic reticulum stress in rheumatic disease.

Authors:  Fatemeh Navid; Robert A Colbert
Journal:  Nat Rev Rheumatol       Date:  2016-12-01       Impact factor: 20.543

Review 4.  Physical activity in idiopathic inflammatory myopathies: two intervention proposals based on literature review.

Authors:  Rossella Talotta; Irene Porrello; Roberto Restuccia; Ludovico Magaudda
Journal:  Clin Rheumatol       Date:  2021-10-19       Impact factor: 2.980

5.  Limitations of a single-point evaluation of anti-MDA5 antibody, ferritin, and IL-18 in predicting the prognosis of interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis.

Authors:  Yoshinao Muro; Kazumitsu Sugiura; Masashi Akiyama
Journal:  Clin Rheumatol       Date:  2012-12-19       Impact factor: 2.980

Review 6.  Idiopathic inflammatory myopathies.

Authors:  Mazen M Dimachkie; Richard J Barohn; Anthony A Amato
Journal:  Neurol Clin       Date:  2014-08       Impact factor: 3.806

Review 7.  Idiopathic inflammatory myopathies.

Authors:  Mazen M Dimachkie; Richard J Barohn
Journal:  Semin Neurol       Date:  2012-11-01       Impact factor: 3.420

8.  Serum level of soluble CX3CL1/fractalkine is elevated in patients with polymyositis and dermatomyositis, which is correlated with disease activity.

Authors:  Fumihito Suzuki; Tetsuo Kubota; Yasunari Miyazaki; Kinya Ishikawa; Masashi Ebisawa; Shunsei Hirohata; Takashi Ogura; Hidehiro Mizusawa; Toshio Imai; Nobuyuki Miyasaka; Toshihiro Nanki
Journal:  Arthritis Res Ther       Date:  2012-03-06       Impact factor: 5.156

9.  Increased levels of eotaxin and MCP-1 in juvenile dermatomyositis median 16.8 years after disease onset; associations with disease activity, duration and organ damage.

Authors:  Helga Sanner; Thomas Schwartz; Berit Flatø; Maria Vistnes; Geir Christensen; Ivar Sjaastad
Journal:  PLoS One       Date:  2014-03-19       Impact factor: 3.240

10.  Serum Interleukin-18 Level is Associated With Disease Activity and Interstitial Lung Disease in Patients With Dermatomyositis.

Authors:  Yuan Yang; Geng Yin; Jingcheng Hao; Qibing Xie; Yi Liu
Journal:  Arch Rheumatol       Date:  2017-04-11       Impact factor: 1.472

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.